Expert review of pharmacoeconomics & outcomes researchHumansGlucagon-Like PeptidesRetrospective StudiesFemaleOverweight
Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
Prachi Arora, Wojciech Michalak, Zhenxiang Zhao, Megan Fiasconaro, Yu Hong, Xin Zhao, Bríain Ó Hartaigh, Sara Alvarez, Angela Fitch
Published: 202510.1080/14737167.2025.2570688
Abstract
BACKGROUND: Patients with obesity or overweight are at increased risk for obesity-related complications (ORCs), including cardiovascular disease. Treatment with once-weekly (OW) semaglutide 2.4 mg has demonstrated clinical efficacy, however its impac…
Preview only. Read the full abstract at the source